Functional analysis of antigen-specific T lymphocytes by serial measurement of gene expression in peripheral blood mononuclear cells and tumor specimens

Journal of Immunology

Volumn 163, Issue 12, 1999, Pages 6867-6875

  Kammula, Udai S ^a   Lee, Kang Hun ^a   Riker, Adam I ^a   Wang, Ena ^a   Ohnmacht, Galen A ^a   Rosenberg, Steven A ^a   Marincola, Francesco M ^a,b  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AUTOANTIGEN; TUMOR ANTIGEN; TUMOR VACCINE;

ANTIGEN SPECIFICITY; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; GENE EXPRESSION; HUMAN; HUMAN CELL; IMMUNE RESPONSE; MELANOMA; MONONUCLEAR CELL; PRIORITY JOURNAL; QUANTITATIVE ASSAY; T LYMPHOCYTE; VACCINATION;

BIOPSY, NEEDLE; CANCER VACCINES; CYTOTOXICITY TESTS, IMMUNOLOGIC; EPITOPES, T-LYMPHOCYTE; FLUORESCENT ANTIBODY TECHNIQUE, DIRECT; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INTERFERON TYPE II; LEUKOCYTES, MONONUCLEAR; MELANOMA; PEPTIDES; RNA, MESSENGER; T-LYMPHOCYTE SUBSETS; TUMOR CELLS, CULTURED;

EID: 0032715902     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (21)

1. Wolfel, T., E. Klehmann, C. Muller, K. H. Schutt, K. H. Meyer zum Buschenfelde, and A. Knuth. 1989. Lysis of human melanoma cells by autologous cytolytic T cell clones: identification of human histocompatibility leukocyte antigen A2 as a restriction element for three different antigens. J. Exp. Med. 170:797.
2. Boon, T., P. G. Coulie, and B. Van den Eynde. 1997. Tumor antigens recognized by T cells, Immunol. Today 18:267.
3. Rosenberg, S. A. 1997. Cancer vaccines based on the identification of genes encoding cancer regression antigens. Immunol. Today 18:175.
4. Kawakami, Y., S. Eliyahu, C. H. Delgado, P. F. Robbins, K. Sakaguchi, E. Appella, J. R. Yannelli, G. J. Adema, T. Miki, and S. A. Rosenberg. 1994. Identification of a human melanoma antigen recognized by tumor-infiltrating lymphocytes associated with in vivo tumor rejection. Proc. Natl. Acad. Sci. USA 91:6458.
5. Rosenberg, S. A., J. C. Yang, D. Schwartzentruber, P. Hwu, F. M. Marincola, S. L. Topalian, N. P. Restifo, E. Dufour, L. Schwartzberg, P. Spiess, et al. 1998. Immunologic and therapeutic evaluation of a synthetic tumor associated peptide vaccine for the treatment of patients with metastatic melanoma. Nat. Med. 4:321.
6. Hu, X., N. G. Chakraborty, J. R. Sporn, S. H. Kurtzman, M. T. Ergin, and B. Mukherji. 1996. Enhancement of cytolytic T lymphocyte precursor frequency in melanoma patients following immunization with the MAGE-1 peptide loaded antigen presenting cell-based vaccine. Cancer Res. 56:2479.
7. Altman, J. D., P. H. Moss, P. R. Goulder, D. H. Barouch, M. G. McHeyzer-Williams, J. I. Bell, A. J. McMichael, and M. M. Davis. 1996. Phenotypic analysis of antigen-specific T lymphocytes [published erratum appears in Science 1998 19;280:1821]. Science 274:94.
8. Rivoltini, L., K. C. Baracchini, V. Viggiano, Y. Kawakami, A. Smith, A. Mixon, N. P. Restifo, S. L. Topalian, T. B. Simonis, S. A. Rosenberg, and F. M. Marincola. 1995. Quantitative correlation between HLA class I allele expression and recognition of melanoma cells by antigen specific cytotoxic T lymphocytes. Cancer Res. 55:3149.
9. Cormier, J. N., M. L. Salgaller, T. Prevette, K. C. Barracchini, L. Rivoltini, N. P. Restifo, S. A. Rosenberg, and F. M. Marincola. 1997. Enhancement of cellular immunity in melanoma patients immunized with a peptide from MART-1/Melan A. Cancer J. Sci. Am. 3:37.
10. Rosenberg, S. A., J. C. Yang, S. L. Topalian, D. J. Schwartzentruber, J. S. Weber, D. R. Parkinson, C. A. Seipp, J. H. Einhorn, and D. E. White. 1994. Treatment of 283 consecutive patients with metastatic melanoma or renal cell cancer using high-dose bolus interleukin 2. JAMA 271:907.
11. Lee, K.-H., E. Wang, M.-B. Nielsen, J. Wunderlich, S. Migueles, M. Connors, S. M. Steinberg, S. A. Rosenberg, and F. M. Marincola. 1999. Increased vaccine-specific T cell frequency after peptide-based vaccination correlates with increased susceptibility to in vitro stimulation hut does not lead to tumor regression. J. Immunol. 163:6292.
12. Heid, C. A., J. Stevens, K. J. Livak, and P. M. Williams. 1996. Real time quantitative PCR. Genome Res. 6:986.
13. Kruse, N., M. Pette, K. Toyka, and P. Rieckmann. 1997. Quantification of cytokine mRNA expression by RT PCR in samples of previously frozen blood. J. Immunol. Methods 210:195.
14. Pockaj, B. A., R. M. Sherry, J. P. Wei, J. R. Yannelli, C. S. Carter, S. F. Leitman, J. A. Carasquillo, S. M. Steinberg, S. A. Rosenberg, and J. C. Yang. 1994. Localization of 111 indium-labeled tumor infiltrating lymphocytes to tumor in patients receiving adoptive immunotherapy: augmentation with cyclophosphamide and correlation with response. Cancer 73:1731.
15. Romero, P., P. R. Dunbar, D. Valmori, M. Pittet, G. S. Ogg, D. Rimoldi, J. L. Chen, D. Lienard, J. C. Cerottini, and V. Cerundolo, 1998. Ex vivo staining of metastatic lymph nodes by class I major histocompatibility complex tetramers reveals high numbers of antigen-experienced tumor-specific cytolytic T lymphocytes. J. Exp. Med. 188:1641.
16. Fuchs, E. J., and P. Matzinger. 1996. Is cancer dangerous to the immune system? Semin. Immunol. 8:271.
17. Matzinger, P. 1998. An innate sense of danger. Semin. Immunol. 10:399.
18. Marincola, F. M., E. M. Jaffe, D. J. Hicklin and S. Ferrone. 1999. Escape of human solid tumors from T cell recognition: molecular mechanisms and functional significance. Adv. Immunol. In press.
19. Wojtowicz-Praga, S. 1997. Reversal of tumor-induced immunosuppression: a new approach to cancer therapy. J. Immunother. 20:165.
20. Hahne, M., D. Rimoldi, M. Schroter, P. Romero, M. Schreier, L. E. French, P. Schneider, T. Bornand, A. Fontana, D. Lienard, J.-C. Cerottini, and J. Tschopp. 1996. Melanoma cell expression of Fas (Apo-1/CD95) ligand: implications for tumor immune escape. Science 274:1363.
21. Ochsenbein, A. F., P. Klenerman, U. Karrer, B. Ludewig, M. Pericin, H. Hengartner and R. M. Zinkernagel. 1999. Immune suerveillance against a solid tumor fails because of immunological ignorance. Proc. Natl. Acad. Sci. USA 96, 2233.